Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL5792939 | 0.79 | LMNA (0.54) | LMNASMN1; SMN2NPC1RAB9AHPGD | |
| Ammonia Solution, Strong SCHEMBL5792944 | 0.79 | LMNA (0.54) | LMNASMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL13568996 | 0.76 | POLB (0.72) | LMNAKMT2AMAPTRECQLALDH1A1 | |
| SCHEMBL12443388 | 0.74 | MEN1 (0.64) | RAB9AKMT2AMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL12443389 | 0.73 | MAPK1 (0.77) | KMT2AMAPTRECQLALDH1A1POLB | |
| SCHEMBL30117342 | 0.72 | RAB9A (0.77) | NPC1RAB9ARECQLALDH1A1POLB | |
| SCHEMBL28937953 | 0.72 | RAB9A (0.77) | NPC1RAB9ARECQLALDH1A1POLB | |
| SCHEMBL13569107 | 0.72 | MAPT (0.66) | LMNANPC1RAB9AKMT2AMAPT | |
| SCHEMBL8011652 | 0.71 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9AKMT2AMAPT | |
| SCHEMBL8011653 | 0.71 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9AKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125746-A1 | METHOD OF PREVENTING OR TREATING TREATMENT-INDUCED GASTROINTESTINAL INJURY | YU JIAN (US) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125746-A1 | METHOD OF PREVENTING OR TREATING TREATMENT-INDUCED GASTROINTESTINAL INJURY | FABP2, SI, ALPI | LMNA 1555/4885SMN1; SMN2 2335/4885NPC1 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.